Dobson C M, Myskow M W, Krajewski A S, Carpenter F H, Horne C H
Department of Pathology, University of Newcastle upon Tyne, U.K.
J Pathol. 1987 Nov;153(3):203-12. doi: 10.1002/path.1711530304.
We have performed a single blind trial to assess the value of the monoclonal antibodies MB1 and MT1 in lymphoma classification. Sixty cases of non-Hodgkin's lymphoma (NHL) were stained with MB1 and MT1 using an indirect immunoperoxidase technique in paraffin sections. The majority of B tumours (27/33) stained with MB1, and most of the T tumours (24/27) stained with MT1. The MB1 antibody often produced rather weak staining but it was apparently highly specific for B cells, with only three (3/27) of the T tumours (two cases of 'malignant histiocytosis' of the intestine (MHI) and one pleomorphic T-cell lymphoma) displaying 'false' positivity. The MT1 antibody generally produced very strong staining, but it was not very selective, with 14/33 of the B lymphomas displaying 'false' positivity. the cross-reactivity observed in 17 cases led to only three misdiagnoses, two B tumours being designated as T lymphomas and one T tumour being designated as a B lymphoma. In a few cases (7/17), dual staining with both antibodies precluded firm diagnosis. In other cases (6/17), classification was possible despite some of the tumour cells showing dual staining. The seventeenth case was a plasmacytoma displaying MT1 positivity only. While the monoclonal antibodies MB1 and MT1 are of use in classifying lymphomas in paraffin section, they are not entirely lineage-specific, and the uncritical use of these two reagents alone may give rise to misdiagnosis; the use of a panel of monoclonal antibodies may yield more accurate results. As with any immunohistochemical marker, their limitations should be recognized; interpretation must be judicious and always in the context of the histological appearances.
我们进行了一项单盲试验，以评估单克隆抗体MB1和MT1在淋巴瘤分类中的价值。采用间接免疫过氧化物酶技术，对60例非霍奇金淋巴瘤（NHL）石蜡切片进行MB1和MT1染色。大多数B细胞肿瘤（27/33）被MB1染色，大多数T细胞肿瘤（24/27）被MT1染色。MB1抗体通常产生较弱的染色，但显然对B细胞具有高度特异性，只有3例（3/27）T细胞肿瘤（2例肠道“恶性组织细胞增多症”（MHI）和1例多形性T细胞淋巴瘤）显示“假”阳性。MT1抗体通常产生非常强的染色，但选择性不强，33例B淋巴瘤中有14例显示“假”阳性。17例中观察到的交叉反应仅导致3例假诊断，2例B细胞肿瘤被误诊为T细胞淋巴瘤，1例T细胞肿瘤被误诊为B细胞淋巴瘤。在少数病例（7/17）中，两种抗体的双重染色妨碍了明确诊断。在其他病例（6/17）中，尽管一些肿瘤细胞显示双重染色，但仍可进行分类。第17例是仅显示MT1阳性的浆细胞瘤。虽然单克隆抗体MB1和MT1可用于石蜡切片中淋巴瘤的分类，但它们并非完全具有谱系特异性，单独不加批判地使用这两种试剂可能会导致误诊；使用一组单克隆抗体可能会产生更准确的结果。与任何免疫组织化学标志物一样，应认识到它们的局限性；解释必须审慎，且始终结合组织学表现。
